SAB Biotherapeutics (SABS) Liabilities and Shareholders Equity (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $248.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 551.81% year-over-year to $248.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $634.9 million (up 220.63% YoY) and the FY2025 annual result came in at $172.8 million, up 291.01% from the prior year.
• Liabilities and Shareholders Equity rose to $248.5 million in Q1 2026, from $172.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $248.5 million in Q1 2026 to a low of $28.3 million in Q3 2023.
• A 5-year average of $78.0 million and a median of $53.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 55.09% — and 2026, when it surged 551.81%.
• Tracing SABS's Liabilities and Shareholders Equity over 5 years: stood at $50.9 million in 2022, then surged by 64.9% to $83.9 million in 2023, then tumbled by 47.35% to $44.2 million in 2024, then surged by 291.01% to $172.8 million in 2025, then surged by 43.78% to $248.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $248.5 million (Q1 2026), $172.8 million (Q4 2025), and $183.4 million (Q3 2025), per Business Quant data.